



<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office  List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	

## U.S. PATENT DOCUMENTS











Examiner Initial	No.	Document Number	Date	Name	Relevant pages
<i>msj</i>	1.	5,874,471	2/23/1999	Waugh	
<i>msj</i>	2.	5,891,459	4/6/1999	Cooke et al.	
<i>msj</i>	3.	6,337,321 B1	1/8/2002	Cooke et al.	
<i>msj</i>	4.	US 2002/0013288 A1	1/31/2002	Cooke et al.	










## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes   No










## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)










<i>msj</i>	5.	Pearson et al. "Neonatal Pulmonary Hypertension," <u>N Engl J Med</u> , <b>344(24)</b> : 1832-1838. (June 12 2001).
<i>msj</i>	6.	Gebhardt et al. "Treatment of Cirrhotic Rats with L-Ornithine-L-Aspartate Enhances Urea Synthesis and Lowers Serum Ammonia Levels," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , <b>283(1)</b> : 1-6 (1997).
<i>msj</i>	7.	Kurowka, "Nitric Oxide Therapies in Vascular Diseases," <u>Current Pharmaceutical Design</u> , <b>8</b> : 155-166 (2002).
<i>msj</i>	8.	Morrow, "The Isoprostanes: Their Quantification as an Index of Oxidant Stress Status in Vivo," <u>Drug Metabolism Reviews</u> , <b>32(3&amp;4)</b> : 377-385 (2000).





FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
List of Documents Cited by Applicant		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	9.	Suzuki et al. "Effect of Local Delivery of L-Arginine on In-stent Restenosis in Humans," <u>The American Journal Of Cardiology</u> , 89: 363-367 (February 15, 2002).	
	10.	Benedetto et al. "Increased L-citrulline/L-arginine plasma ratio in severe preclampsia," <u>Obstet Gynecol</u> , 96(3): 395-399 (September 2000). (ABSTRACT)	
	11.	Baumgartner et al. "Hyperammonemia with reduced ornithine, arginine and praline: a new inborn error caused by a mutation in the gene encoding delta(1)-pyrroline-5-carboxylate synthase," <u>Hum Mol Genet</u> , 9(19): 2853-2858 (November 22, 2000). (ABSTRACT)	
	12.	Chwalisz et al. "Role of nitric oxide in implantation and menstruation," <u>Hum Reprod</u> , 15(suppl 3): 96-111 (August 2000). (ABSTRACT)	
	13.	Mori et al. "Regulation of nitric oxide production by arginine metabolic enzymes," <u>Biochem Biophys Res Commun</u> , 275(3): 715-719 (September 7 2000). (ABSTRACT)	
	14.	Muriel, "Regulation of nitric oxide synthesis in the liver," <u>J Appl Toxicol</u> , 20(3): 189-195 (May-June 2000). (ABSTRACT)	
	15.	Bredt, "Endogenous nitric oxide synthesis: biological functions and pathophysiology," <u>Free Radic Res</u> , 31(6): 577-596 (December 1999). (ABSTRACT)	
	16.	Akashi et al. "Citrulline, a novel compatible solute in drought-tolerant wild watermelon leaves, is an efficient hydroxyl radical scavenger," <u>FEBS Lett</u> , 508(3): 438-442 (November 23 2001). (ABSTRACT)	
	17.	Ikeda et al. "Cardiovascular effects of citrulline in ischemia/ reperfusion injury via a non-nitric oxide-mediated mechanism," <u>Methods Find Exp Clin Pharmacol</u> , 22(7): 563-571 (September 2000). (ABSTRACT)	
	18.	Stuhlinger et al. "Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor," <u>JAMA</u> , 287(11): 1420-1426 (March 20, 2002). (ABSTRACT)	

<b>FORM PTO-1449 U.S. Department of Commerce</b> Patent and Trademark Office  List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	19.	Stuhlinger et al. "Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine," <u>Circulation</u> , <b>104(21)</b> : 2569-2575 (November 20, 2001). (ABSTRACT)	
	20.	Dulak et al. "Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells," <u>Arterioscler Thromb Vasc</u> , <b>20(3)</b> : 659-666 (March 2000). (ABSTRACT)	
	21.	Cooke, "Does ADMA cause endothelial dysfunction?" <u>Arterioscler Thromb Vasc Biol</u> , <b>20(9)</b> : 2032-2037 (September 2000). (ABSTRACT)	
	22.	Cooke et al. "Atherogenesis and the arginine hypothesis," <u>Curr Atheroscler Rep</u> , <b>3(3)</b> : 252-259 (May 2001). (ABSTRACT)	
	23.	Cooke, "The endothelium: a new target for therapy," <u>Vasc Med</u> , <b>5(1)</b> : 49-53 (2000). (ABSTRACT)	
	24.	Boger et al. "An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes," <u>J Am Cardiol</u> , <b>36(7)</b> : 2287-2295 (December 2000). (ABSTRACT)	
	25.	<del>Boger et al. "Is asymmetric dimethylarginine a novel mark of atherosclerosis?" <u>Circulation</u>, <b>101(14)</b>: 160-161 (April 11, 2000). (ABSTRACT)</del>	
	26.	Uemura et al. "Rapid and efficient vascular transport of arginine polymers inhibits myointimal hyperplasia," <b>102(21)</b> : 2629-2635 (November 21, 2000). (ABSTRACT)	
	27.	Jang et al. "Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine," <u>Circulation</u> , <b>102(12)</b> : 1414-1419 (September 19 2000). (ABSTRACT)	
	28.	Lundman et al. "Mild-to-moderate hypertriglycerida in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine," <u>J Am Coll Cardiol</u> , <b>38(1)</b> : 111-116 (July 2001). (ABSTRACT)	


FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office  List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	29.	<del>Maxwell et al. "Endothelial dysfunction in hypercholesterolemia is reserved by a nutritional product designed to enhance nitric oxide activity," <u>Cardiovasc Drugs Ther</u>, 14(3): 309-316 (June 2000). (ABSTRACT)</del>	
mm	30.	Chan et al. "Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans," <u>Arterioscler Thromb Vasc Biol</u> , 20(4): 1040-1046 (April 2000). (ABSTRACT)	
mm	31.	Maxwell et al. "L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide production," <u>J Appl Physiol</u> , 90(3): 933-938 (March 2001). (ABSTRACT)	
	32.	<del>Maxwell et al. "Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar," <u>Vasc Med</u>, 5(1): 11-19 (2000). (ABSTRACT).</del>	
mm	33.	Schwarzacher et al. "effects of stenting on adjacent vascular distensibility and neointima formation: role of nitric oxide," <u>Vasc Med</u> , 6(3): 139-144 (2001). (ABSTRACT)	
mm	34.	Schwarzacher et al "Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty," <u>Circulation</u> , 95(7): 1863-1869 (April 1, 1997). (ABSTRACT)	
mm	35.	Niebauer et al. "Local L-arginine delivery after balloon angioplasty reduces monocyte binding and induces apoptosis," <u>Circulation</u> , 100(17): 1830-1835 (October 26, 1999). (ABSTRACT)	
mm	36.	Niebauer et al. "Gene transfer of nitric oxide synthase: effects on endothelial biology," <u>J Am Coll Cardiol</u> , 34(4): 1201-1207 (October 1999). (ABSTRACT)	
mm	37.	Kurowska, "Nitric oxide therapies in vascular diseases," <u>Curr Pharm Des</u> , 8(3): 155-166 (2002). (ABSTRACT)	
	38.	<del>Vosatka, "Persistent pulmonary hypertension of the newborn," <u>N Engl J Med</u>, 346(11): 864 (March 14, 2002). (ABSTRACT)</del>	

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office  List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	39.	Waugh et al. "Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results," <u>J Natl Med Assoc</u> , <b>93(10)</b> : 363-371 (October 2001). (ABSTRACT)	
	40.	O'Connor et al. "Nonalcoholic fatty liver (NASH syndrome)," <u>Gastroenterologist</u> , <b>5(4)</b> : 316-329 (December 1997). (ABSTRACT)	
	41.	Bruno et al. "Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel," <u>Invest New Drugs</u> , <b>19(2)</b> : 163-169 (May 2001). (ABSTRACT)	
	42.	Gur et al. "Determination of hepatic zinc content in chronic liver sdisease due to hepatitis Bv virus," <u>Hepatogastroenterology</u> , <b>45(20)</b> : 472-476 (March-April 1998). (ABSTRACT)	
	43.	Durand et al. "Acute liver failure in infancy: a 14-year experience of a pediatric liver transplantation center," <u>J Pediatr</u> , <b>139(6)</b> : 871-876 (December 2000). (ABSTRACT)	
	44.	Maier et al "Activities of urea-cycle enzymes in chronic liver disease," <u>Klin Wochenschr</u> , <b>57(13)</b> : 661-665 (July 3, 1979). (ABSTRACT)	
	45.	Cohen et al. "The SGOT/SGPT ratio--an indicator of alcoholic liver disease," <u>Dig Dis Sci</u> , <b>24(11)</b> : 835-838 (November 1979). (ABSTRACT)	
	46.	<del>Alves et al. "The SGOT/SGPT rataio in alcoholic liver disease," <b>3(4)</b>: 255-260 (July-August 1981). (ABSTRACT)</del>	
	47.	Treem et al. "Disorders of the mitochondria," <u>Semin Liver Dis</u> , <b>18(3)</b> : 237-253 (1998). (ABSTRACT)	
	48.	Fearon et al., "Genetic Analysis of Carbamyl Phosphate Synthetase I Deficiency," <u>Human Genetics</u> , Vol. 70, No. 3, pp. 207-210 (1985).	

<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	49.	Finckh et al., "Prenatal Diagnosis of Carbamoyl Phosphate Synthetase I Deficiency by Identification of a Missense Mutation in CPS1," <u>Human Mutation</u> , Wiley-Liss, NY, Vol. 12, No. 3, pp. 206-211 (1998).	
	50.	Ghishan et al., "Polymerase Chain Reaction (PCR) Detectable Polymorphisms in the Prenatal Diagnosis of Carbamyl Phosphate Synthetase I Deficiency," <u>Gastroenterology</u> , Vol. 106, No. 4 Suppl., p. A1028 (1994).	
	51.	Haraguchi et al., "Cloning and Sequence of a cDNA Encoding Human Carbamyl Phosphate Synthetase I Molecular Analysis of Hyperammonemia," <u>Gene</u> , Vol. 107, No. 2, pp. 335-340 (1991).	
	52.	Vnencak-Jones et al., "Efficacy of Prenatal DNA Testing for Carbamyl Phosphate Synthetase I Deficiency," <u>Am. Jour. Human Genetics</u> , Vol. 51, No. 4 Suppl., p. A357 (1992).	
	53.	Alonso et al., "Affinity Cleavage of Carbomoyl-Phosphate Synthetase I Localizes Regions of the Enzyme Interacting with the Molecule of ATP that Phosphorylates Carbamate," <u>Eur. J. Biochem</u> , p. 377-384, (1995).	
	54.	Guillou et al., "Escherichia Coli Carbamoyl-Phosphate Synthetase: Domains of Glutaminase and Synthetase Subunit Interaction," <u>Proc. Natl. Acad. Sci. USA</u> , p. 8304-8308, ( November 14, 1989).	
	55.	Guy et al., "Substructure of the Amidotransferase Domain of Mammalian Carbamyl Phosphate Synthetase," <u>J. Biol. Chem</u> , Vol. 270 ( No. 5), p. 2190-2197, ( February 3, 1995).	
	56.	Lagace et al., "Rat Carbamyl-Phosphate Synthetase I Gene," <u>J. Biol. Chem</u> , Vol. 262 ( No. 22), p. 10415-10418, ( August 5, 1987).	
	57.	Nyunoya et al., "Characterization and Derivation of the Gene Coding for Mitochondrial Carbamyl Phosphate Synthetase I of Rat," <u>J. Biol. Chem.</u> , Vol. 260 ( No. 16), p. 9346-9356, ( August 5, 1985).	

<b>FORM PTO-1449 U.S. Department of Commerce</b> Patent and Trademark Office  List of Documents Cited by Applicant		Attorney Docket No.:	1242/58
		Serial No.:	10/785,374
		Filing Date:	February 24, 2004
		First Named Inventor:	Summar et al.
		Examiner:	
		Group:	
	58.	Mize, et al., "Urea Cycle Disorders" Mol. Genet. Basis. Neurol. Dis., 2 <sup>nd</sup> ed., 1151-1174 (1997).	
	59.	Hoshida et al., J. Clin. Invest. Vol. 91(5), p. 1884-1887 (May 1993).	
	60.	Erllich et al., Science Vol. 252:1143-1151 (June 1991).	
	61.	MacCallum, "Detection of PCR Amplified Products" PCR Essential Data, p. 99-127 (1995).	


EXAMINER



DATE CONSIDERED

9/10/07

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office  List of Documents Cited by Applicant	Application No.:	10/785,374
	Filing Date:	February 24, 2004
	First Named Inventor:	Summar et al.
	Group:	1638
	Examiner:	To be assigned
Attorney Docket No.:		1242/58

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
<i>DRD</i>	1	2001/0056068	12/27/2001	Chwalisz et al.	
<i>DRD</i>	2	6,337,321 B1	1/8/2002	Cooke et al.	
<i>DRD</i>	3	6,642,208 B2	11/4/2003	Cooke et al.	
<i>DRD</i>	4	6,646,006 B2	11/11/2003	Cooke et al.	
<i>DRD</i>	5	5,767,160	6/16/1998	Kaesemeyer	
<i>DRD</i>	6	5,286,739	2/15/1994	Kilbourn et al.	
<i>DRD</i>	7	6,689,810	2/10/2004	Martin	
<i>DRD</i>	8	5,873,359	2/23/1999	Zapol et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T

## OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T

EXAMINER Diana B DATE CONSIDERED 9/10/07


\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b>		Application No.:		10/785,374		
Patent and Trademark Office		Filing Date:		February 24, 2004		
List of Documents Cited by Applicant		First Named Inventor:		Summar et al.		
		Group:		1638		
		Examiner:		To be assigned		
		Attorney Docket No.:		1242/58		
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear	
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
<b>OTHER DOCUMENTS</b>						
Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.				T
<i>ms</i>		International Search Report and Written Opinion corresponding to PCT international application no. PCT/US05/06081 dated December 23, 2005.				
<i>ms</i>		AMIN ET AL., "Arginine supplementation prevents necrotizing enterocolitis in the premature infant", <u>Journal of Pediatrics</u> , <b>140</b> (4): April 2002, 425-431.				
<i>ms</i>		MIZUTANI ET AL., "Oral Administration of Arginine and Citrulline in the Treatment of Lysinuric Protein Intolerance", <u>Tohoku J. of Exp. Med.</u> , <b>142</b> : 1998, 15-24.				
<i>ms</i>		DAVIES ET AL., "Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation", <u>Bone Marrow Transplantation</u> , <b>17</b> : June 1996, 1119-1125.				
<i>ms</i>		VASSAL ET AL. "Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation", <u>Cancer Chemo. Phar.</u> , <b>37</b> ., 1996, 247-253.				

EXAMINER *Diana P* DATE CONSIDERED 9/10/07

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b>		Application No.:	10/785,374
<b>Patent and Trademark Office</b>		Filing Date:	February 24, 2004
List of Documents Cited by Applicant		First Named Inventor:	Summar et al.
		Group:	1638
		Examiner:	To be assigned
		Attorney Docket No.:	1242/58




U.S. PATENT DOCUMENTS					
Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T.

OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T.
md	A	Notification Concerning Transmittal of Copy of International Preliminary Report on Patentability corresponding to PCT international application no. PCT/US05/06081 dated September 8, 2006.	


EXAMINER



DATE CONSIDERED

9/10/07




\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  List of Documents Cited by Applicant  	Application No.:	10/785,374
	Filing Date:	February 24, 2004
	First Named Inventor:	Summar et al.
	Group:	1638
	Examiner:	To be assigned
	Attorney Docket No.:	1242/58


## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pgs, columns, lines where relevant passages appear	Translation Y / N
	A	WO 2001/56068 A1	12/27/2001	Nicon Corporation		Abstract in English
	B	WO 2000/06151 A1	02/10/2000	Kuhrts		
	C	WO 2000/73322 A	12/07/2000	Vanderbilt University		
	D	WO 1994/16740 A	08/04/1994	Brigham and Women's Hospital		
	E	AU 3460571 A	04/19/1973	Richardson-Merrell S.p.A.		




## OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
	F	Barr et al. Effect of cardiopulmonary bypass on urea cycle intermediates and nitric oxide levels after congenital heart surgery. The Journal of Pediatrics, Vol. 142, no. 1, (2003), pp.26-30	


EXAMINER Diana BZ DATE CONSIDERED 9/10/07

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  List of Documents Cited by Applicant	Application No.:	10/785,374
	Filing Date:	February 24, 2004
	First Named Inventor:	Summar et al.
	Group:	1638
	Examiner:	To be assigned
	Attorney Docket No.:	1242/58

 	G	EMBASE Database Accession Number EMB-2003218186 [on-line] Elsevier Science Publishers, Amsterdam, NL; 2003-05-27	
	H	BIOSIS Database Accession Number PREV199699075415 [on-line] Biosciences Information service, Philadelphia, PA, US; 1996	
	I	EMBASE Database Accession Number EMB-1990075119 [on-line] Elsevier Science Publishers, Amsterdam, NL; 1990	
	J	MEDLINE Database Accession Number NLM7600831 [on-line] US National Library of Medicine (NLM), Bethesda, MD, US; July 1995	
	K	BIOSIS Database Accession Number PREV200400055833 [on-line] Biosciences Information service, Philadelphia, PA, US; December 2003	
	L	BIOSIS Database Accession Number PREV200200378590 [on-line] Biosciences Information service, Philadelphia, PA, US; May 2002	
	M	BIOSIS Database Accession Number PREV199800177848 [on-line] Biosciences Information service, Philadelphia, PA, US; February 1998	
	N	BIOSIS Database Accession Number PREV199799686392 [on-line] Biosciences Information service, Philadelphia, PA, US; 1997	

EXAMINER



DATE CONSIDERED



\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.